We recommend that patients with cardiac diseases, hypertension, or diabetes that are treated with ACE2-increasing drugs may be at higher risk for severe COVID-19 infection and that, therefore, ACE2-modulating therapies like ACE inhibitors or ARBs should be supervised attentively. Here, ACE is linked to heart disorder.